BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Trial Profile

BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 27 Nov 2017 According to a Biohaven Pharmaceutical Holding Company media release, results from BHV3000-301 and BHV3000-302 trials are expected to support regulatory submission to the US FDA.
    • 16 Nov 2017 According to a Biohaven Pharmaceutical Holding Company media release, enrollment is completed for this trial (n=>1400) (Study BHV3000-301).
    • 16 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to a Biohaven Pharmaceutical Holding Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top